Atrium Medical Announces Formation of Biosurgery Division

HUDSON, NH, Jan 12 (MARKET WIRE) --
Atrium Medical Corporation(R) is pleased to announce the formation of its
newest med-tech specialty healthcare division, Atrium Biosurgery(TM).
Atrium Biosurgery is dedicated to the development of pioneering
advancements in biological, mechanical and therapeutic solutions for soft
tissue healing following trauma, surgery and or other interventional
procedures that require improved patient recovery and prospects for
improved healing outcomes. This newest global expansion will complement
Atrium's other professional Healthcare Divisions -- Cardiovascular
Interventions (CVI) and Cardiothoracic Surgery (CTS) -- by continuing the
company's tradition of providing state-of-the-art medical device
technology for patients around the globe.

Atrium Biosurgery products include Atrium's first-to-market Omega 3
Bioabsorbable Oil Fatty Acid (O3FA) coated medical devices. This novel
technology combines Atrium's ProLite(TM) and ProLite Ultra(TM) brand
polypropylene surgical mesh products commonly used in soft tissue and
hernia repair with a proprietary, pharmaceutical grade Omega 3
bio-absorbable coating. Atrium's innovative discovery of combining an
inert thin wall polypropylene mesh with an all natural Omega 3 biological
coating in clinical use, and in numerous pre-clinical studies, has
demonstrated minimization of visceral tissue attachment as well as
reductions in both foreign body reaction and inflammation following
surgical intervention. Such technology can result in a preferred, well
healed, reinforced surgical repair. These soft tissue reinforcement
devices include Atrium C-QUR(TM) Mesh, C-QUR Edge(TM) Mesh, and the
recently launched C-QUR Lite(TM) Surgical Mesh which combine a proven
inert polymer material with an advanced Omega 3 coating technology --
indicated for use in the surgical repair and reinforcement of soft
tissue, including abdominal and inguinal hernia surgery, common surgical
procedures performed more than 700,000 times annually in the US.

With the introduction of the new Atrium Biosurgery Division, the company
is undergoing a substantial expansion program and is anticipating
exceptional growth as several pending new O3FA technology based products
become commercially available in the months and years ahead.

About Atrium(R)

Atrium's vast expertise in medical device technologies for the treatment
of coronary and vascular disease, chest trauma, hernia and soft tissue
injury has brought a number of breakthrough advances in several
diversified healthcare markets including interventional cardiology and
radiology, chest trauma care and thoracic drainage, vascular surgery,
women's health and general surgery. Maintaining a commitment to the
latest ISO13485 Quality Standards, state-of-the-art manufacturing and
automation, cell biology and biomaterial discovery programs, Atrium
continues to excel in those healthcare segments that require more
advanced surgical intervention for improvements in patient outcome. For
more information please call Atrium's Marketing Communications Dept. at
1-800-370-7899 or Google(R) Atrium Medical, and visit us on the web at
www.atriummed.com.

Contact:
Atrium's Marketing Communications Dept.
1-800-370-7899
www.atriummed.com.

Copyright 2009, Market Wire, All rights reserved.

-0-